SHPA’s Residency Program, implemented in 2017, is the first and only structured, formalised, supported and accredited national pharmacy residency program in Australia.
This two-year professional development program:
- provides practice based experiential training
- is targeted at early career pharmacists, or pharmacists entering hospital pharmacy practice after working in other pharmacy practice environments
- offers a diverse program curriculum ensuring residents gain the skills and knowledge to achieve a cohort of competent general level pharmacists.
- is an important step that leads to other professional development pathways, such as advanced practice recognition.
SHPA residency supports pharmacist practitioner development towards competence and performance aligned with Stage 1 (Transition Level) of the Australian Advanced Pharmacy Practice Framework.
The importance of foundation training infrastructures is emphasised in Goal 2 of the International Pharmaceutical Federation’s (FIP) ‘Pharmaceutical Workforce Development Goals’.
Applications for the 2018 round of hospital pharmacy accreditation for the SHPA Residency Program are now closed. Outcomes will be posted shortly.
Over 30 residency programs are provisionally accredited by SHPA. A list of sites is available here.
Programs currently holding provisional accreditation will be subject to a site visit by SHPA surveyors by mid-2018 in expectation of achieving full accreditation.
SHPA’s media release announcing accreditation outcomes on 2 November is available here.
SHPA’s media release announcing accreditation outcomes on 1 December is available here.
SHPA's media release announcing the SHPA Residency Symposium on 29 August 2017 is available here.
SHPA's media release announcing the opening of 2018 Residency Program site accreditation applications is available here.
The Resident of the Year Award is annually bestowed on a resident undertaking SHPA’s Residency Program who has demonstrated excellence in practice and professional improvement.
The award is supported by MIMS and includes:
- SHPA MM2017 registration, travel and accommodation to receive their award.
- Up to $2,000 towards the recipient's professional development e.g. conference attendance/post-graduate study.
- Award certificate
SHPA and MIMS continue to support the profession in recognising excellence in pharmacy practice.
Nominations for the 2017 award are now closed.
- SHPA Accreditation Standards for pharmacy residency programs
- SHPA Residency Program Site Application - example questions
- Evaluation and Assessment Matrix
- SHPA Residency Program Competency Framework
- SHPA Residency Program - Key Principles
- Webinar: Applying for Accreditation as a Residency Program Site
- SHPA Residency Program FAQs
- Instructions for using SHPA Residency mini-PAT
- Transitioning from academic education to professional practice (presentation to ANZAHPE Conference July 2017)
- Compiled Residency Presentations from MM2016
- Purple Pen Podcast #8 with Dr Bob Feroli: Residency/ Medication Safety
- Purple Pen Podcast: SHPA Residency. Learn more about the SHPA Residency Program. Recorded on 5th September 2016 immediately after the inaugural SHPA Residency Symposium
- Building a pharmacy workforce for the future. Australian Journal of Pharmacy September 2016
- SHPA’s Residency Program - delivering the workforce of tomorrow (presentation adapted from SHPA Victorian Pharmacy Manager’s meeting 9 September 2016)
- Residency Programs in Australia (poster presented at American Society of Health-System Pharmacists National Pharmacy Preceptors meeting, Washington DC August 2016)
- Choosing the Right Residence. Australian Journal of Pharmacy May 2016
Residency Project: Andrew Matthews, General Manager, Workforce Transformation
E: email@example.com T: 0408 650 153
• Supporting SHPA Councillor and Chair: Peter Fowler (Tas.)
• Two members of the SHPA Education Reference Group: Dan Guidone (Vic.); Cathy Martin (NSW)
• Director/chief pharmacist of a hospital pharmacy department: Dr Ian Coombes (Qld)
• Pharmacist with experience in training, education, preceptorship and/or professional development: Cameron Phillips (UK*)
• Resident (early career pharmacist): Natalie Maher (SA)
• Pharmacist with expertise in ambulatory clinical services: Dr Chris Freeman (Qld)
• Non-pharmacist health professional (Clinical Pharmacologist and General Physician): Prof Arduino Mangoni (SA)
• NAPSA Representative: Vasilios Sotiropoulos
* Currently undertaking a 12-month fellowship as a visiting researcher in the UK
Project manager: Andrew Matthews